Oncotelic Therapeutics, Inc. (OTLC) Return on equity 2021–2024
Oncotelic Therapeutics, Inc. (OTLC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-65.2%FY2024 · since FY2021: -80.7% → -65.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -65.2% | — |
| FY2021 | -80.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice